Rep. Maria Elvira Salazar Sells Shares of Biogen Inc. (NASDAQ:BIIB)

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $225.71 on Friday. The stock’s fifty day simple moving average is $217.41 and its 200 day simple moving average is $202.26. The stock has a market capitalization of $33.35 billion, a price-to-earnings ratio of 39.95, a PEG ratio of 2.41 and a beta of 0.09. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 52-week low of $138.00 and a 52-week high of $230.49.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays upped their price target on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 29th. TD Cowen boosted their target price on shares of Biogen from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Wedbush increased their target price on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Bank of America decreased their target price on Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research report on Tuesday, July 21st. Finally, Needham & Company LLC lifted their price target on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and a consensus price target of $231.07.

Institutional Trading of Biogen

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Biogen in the second quarter worth $3,453,878,000. Primecap Management Co. CA bought a new position in shares of Biogen during the 2nd quarter worth about $3,274,304,000. Wellington Management Group LLP increased its holdings in shares of Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares during the period. Amundi lifted its stake in shares of Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after buying an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Biogen during the second quarter worth about $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.